Items where authors include "Caley, L."

Article

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2023) Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. Frontiers in Pharmacology, 14. 1207356. ISSN 1663-9812

Proceedings Paper

Caley, L. orcid.org/0000-0001-8957-1018, Zagoya, C., White, H. et al. (3 more authors) (2025) Associations between changes in CFAbd-Score, dietary intake and weight following Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy: preliminary analysis. In: Journal of Cystic Fibrosis. 47th European Cystic Fibrosis Conference, 05 Jun 2024 - 08 Jun 2025, Glasgow, UK. Elsevier .

Gillgrass, L., Caley, L. orcid.org/0000-0001-8957-1018, Zagoya, C. et al. (5 more authors) (2024) P318 Abdominal symptoms after longer term use of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. In: Journal of Cystic Fibrosis. 47th European Cystic Fibrosis Conference, 05 Jun 2024 - 08 Jun 2025, Glasgow, UK. Elsevier .

Caley, L. orcid.org/0000-0001-8957-1018, de Goffau, M.C., Jones, A.M. et al. (6 more authors) (2023) EPS5.01 Change in gut microbiota following elexacaftor/tezacaftor/ivacaftor (ETI) therapy: preliminary analysis. In: Journal of Cystic Fibrosis. 46th European Cystic Fibrosis Conference, 07-10 Jun 2023, Vienna, Austria. Elsevier .

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2022) WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK. In: Journal of Cystic Fibrosis. 45th European Cystic Fibrosis Conference, 08-11 Jun 2022, Rotterdam, The Netherlands. Elsevier .